Form 4: Upstream Bio Director Ronald Renaud Jr. Granted 17,096 Stock Options

Upstream Bio, Inc. Director Ronald C. Renaud Jr. was granted 17,096 stock options with an exercise price of $11.59 per share, vesting over approximately one year.

Summary

• Ronald C. Renaud Jr., a Director of Upstream Bio, Inc. (UPB), was granted 17,096 stock options.
• The transaction date for this grant was June 10, 2025.
• Each stock option has an exercise price of $11.59.
• The options are set to expire on June 9, 2035.
• Vesting for these options will occur upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders of Upstream Bio, Inc., contingent on Mr. Renaud Jr.'s continued service.
• The filing also includes a Substitute Power of Attorney, dated December 19, 2024, appointing Allison Ambrose as attorney-in-fact for several individuals, including Mr. Renaud Jr., to execute SEC filings.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates ongoing director compensation and alignment of interests, but it's a routine filing with no significant new financial or operational news.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the company's stock price increases.
• This is a standard form of compensation for directors, indicating ongoing commitment and incentivization.

Future Outlook

The granted stock options are subject to a vesting schedule, with vesting occurring upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders, provided the director continues his service.

Industry Context

This filing represents a routine insider transaction, specifically the grant of equity compensation to a director, which is a common practice across various industries to incentivize and retain key personnel.

Corporate Governance

Related Party Transactions

• The grant of 17,096 stock options to Ronald C. Renaud Jr., a director of Upstream Bio, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of stock options can lead to potential future dilution if exercised, but also aligns the director's financial interests with the company's stock performance, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The stock options will vest upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders, subject to continued service.
• Following vesting, Ronald C. Renaud Jr. will have the right to exercise these options to acquire common stock of Upstream Bio, Inc. at the specified exercise price.

Key Dates

Keywords

Upstream Bio, UPB, Form 4, Stock Option, Director Compensation, Insider Transaction, Beneficial Ownership, Equity Grant, Corporate Governance